Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

April 19, 2016

Conditions
Richter's Syndrome
Interventions
DRUG

Ofatumumab

"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"

Trial Locations (9)

B15 2TT

Queen Elizabeth Hospital Birmingham, Birmingham

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

CB2 0QQ

Addenbrooke's Hospital, Cambridge

LS9 7TF

St James University Hospital, Leeds

L7 8XP

Royal Liverpool University Hospital, Liverpool

EC1A 7BE

St Bartholomew's Hospital, London

SE5 9RS

Kings College Hospital, London

M20 4BX

Christie Hospital, Manchester

OX3 7LJ

Churchill Hospital, Oxford

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Cancer Research UK

OTHER

collaborator

Oxford University Hospitals NHS Trust

OTHER

collaborator

NCRI CLL Subgroup

UNKNOWN

lead

University of Oxford

OTHER